Ophthalmology
🇪🇺 EMAEMA news and analysis for pharmaceutical BD, investment, and market access
Gain critical insights into global ophthalmology drug development, market trends, and regulatory landscapes. Inform your pharma investment and BD strategy.
Showing 1–3 of 3 articles
Quick answer
NovaPharmaNews Ophthalmology hub for EMA covers 3 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
EMA Issues Positive Opinion for Rexatilux (Ranibizumab) Eye Treatment
MeiraGTx Acquires Botaretigene Sparoparvovec Gene Therapy from Johnson & Johnson for X-linked Retinitis Pigmentosa Treatment
Vabysmo Market Report 2026: Roche's Eye Drug Shows Strong Growth Through 2035 Amid Rising Retinal Disorder Cases
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.